Inhibitors of the corresponding receptors, DMPQ, burixafor, tocilizumab, and reparixin, eliminated the stimulatory effect of MCM on IF and IA (Figure 3e,f), supporting the involvement of PDGFβ, SDF-1α, IL-6, and IL8 in MCM-induced CL1 glioma cell invasion. Here, CXCL8 is linked to glioma.